Cellosaurus OCI-AML3 (CVCL_1844)

Cell line name OCI-AML3
Synonyms OCI AML3; OCI-AML-3; OCI/AML-3; OCI/AML3; OCIAML3
Accession CVCL_1844
Resource Identification Initiative To cite this cell line use: OCI-AML3 (RRID:CVCL_1844)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
From: Ontario Cancer Institute (OCI); Toronto; Canada.
Doubling time: 28 hours (PubMed=25984343); ~35-40 hours (DSMZ).
Microsatellite instability: Stable (MSS) (Sanger).
Sequence variation: DNMT3A p.Arg882Cys (DSMZ).
Sequence variation: Heterozygous for NPM1 p.Trp288Cysfs (c.860_863dupTCTG) (PubMed=16079892).
Omics: Deep exome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: shRNA library screening.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Derived from sampling site: Peripheral blood.
Disease Adult acute myeloid leukemia (NCIt: C9154)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Male
Category Cancer cell line
STR profile Source(s): Cosmic-CLP; DSMZ; PubMed=25877200

Markers:
AmelogeninX
CSF1PO11,12
D13S3178,13
D16S53911,13
D18S5112,18
D21S1129,30
D3S135816
D5S81811,13
D7S8209,10
D8S117910,12
FGA22
Penta D12,13
Penta E11,13
TH018,10
TPOX8,11
vWA17,18
Publications

PubMed=2538684
Wang C., Curtis J.E., Minden M.D., McCulloch E.A.
Expression of a retinoic acid receptor gene in myeloid leukemia cells.
Leukemia 3:264-269(1989)

PubMed=16079892; DOI=10.1038/sj.leu.2403899
Quentmeier H., Martelli M.P., Dirks W.G., Bolli N., Liso A., Macleod R.A.F., Nicoletti I., Mannucci R., Pucciarini A., Bigerna B., Martelli M.F., Mecucci C., Drexler H.G., Falini B.
Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin.
Leukemia 19:1760-1767(2005)

PubMed=16408098; DOI=10.1038/sj.leu.2404081
Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.
JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders.
Leukemia 20:471-476(2006)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=25984343; DOI=10.1038/sdata.2014.35
Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S., East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H., Jiang G., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M., Harrington W., Gelfand E., Green T.M., Tomko M.J., Gopal S., Wong T.C., Li H., Howell S., Stransky N., Liefeld T., Jang D., Bistline J., Hill Meyers B., Armstrong S.A., Anderson K.C., Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P., Golub T.R., Root D.E., Hahn W.C.
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Sci. Data 1:140035-140035(2014)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

Cross-references
Cell line collections DSMZ; ACC-582
Cell line databases/resources CCLE; OCIAML3_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
Cosmic-CLP; 1290455
GDSC; 1290455
LINCS_LDP; LCL-1066
Ontologies BTO; BTO:0004620
EFO; EFO_0006289
Biological sample resources BioSample; SAMN03473107
Gene expression databases GEO; GSM482512
GEO; GSM887469
GEO; GSM888549
GEO; GSM1446756
GEO; GSM1670296
Polymorphism and mutation databases Cosmic; 787467
Cosmic; 975289
Cosmic; 1012110
Cosmic; 1127258
Cosmic; 1245831
Cosmic; 1319546
Cosmic; 1557602
Cosmic; 1582387
Cosmic; 1696140
Cosmic; 1779129
Cosmic; 2131552
Cosmic; 2306232